Article

CORD files for premarket approval with FDA for the SC9 IOL for cataract surgery

Author(s):

CORD, LLC, announced it has submitted a Premarket Approval (PMA) application to the FDA for the Model SC9 IOL for the treatment of cataracts.

The SC9 was developed by Stuart Cumming, MD, FACS, FRCOphth, who has been involved in the development of technology to improve and enhance vision for more than four decades. He holds more than 100 patents related to intraocular lenses.

Cumming designed the Crystalens, approved by the FDA in 2003.

The SC9 lens was designed to treat cataract patients with a single focus spherical optic and a rigid structure to consistently locate the optic in a position intended to provide intermediate vision that is superior to that of a standard monofocal IOL.

CORD is seeking market approval of the SC9 intraocular lens based on the results of more than 300 patients who were followed for a minimum of one year under an approved Investigational Device Exemption (IDE).

Related Videos
Arun Gulani, MD: How the Gni instrument enhances precision and control in cataract surgery
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
© 2024 MJH Life Sciences

All rights reserved.